<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83072">
  <stage>Registered</stage>
  <submitdate>13/08/2008</submitdate>
  <approvaldate>15/09/2008</approvaldate>
  <actrnumber>ACTRN12608000455369</actrnumber>
  <trial_identification>
    <studytitle>A clinical study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist 'Registered trade mark') in comparison to ProHance 'Registered trade mark' (gadoteridol) 0.5 molar in patients referred for contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system.</studytitle>
    <scientifictitle>A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist 'Registered trade mark') in patients referred for contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system (CNS). Protocol number 310123</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ClinicalTrials.gov identifier: NCT00709852</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Central nervous system diseases requiring a contrast-enhanced MRI of the CNS.</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Drug: Gadovist 'Registered trade mark' (Gadobutrol) 1.0 molar; dose 0.1 mmol/kg; route of administration intravenous; duration of treatment is single dose;washout period 24 hours; MRI using steady state sequences.</interventions>
    <comparator>Drug: ProHance 'Registered trade mark' (Gadoteridol) 0.5 molar; dose 0.1 mmol/kg; route of administration intravenous; duration of treatment is single dose; MRI using steady state sequences.</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To demonstrate superiority of combined unenhanced and gadobutrol-enhanced magnetic resonance imaging (MRI), based on degree of enhancement, border delineation, and internal morpholgy.</outcome>
      <timepoint>4 minutes post injection.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To demonstrate noninferiority of combined unenhanced and gadobutrol-enhanced magnetic resonance imaging (MRI), based on number of lesions detected.</outcome>
      <timepoint>4 minutes post injection.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Demonstrate improvement of gadobutrol-enhanced MRI to unenhanced MRI and noninferiority to gadoteridol-enhanced MRI for: exact match of the MRI diagnoses with the final clinical diagnosis using the independent standard of truth evaluation.</outcome>
      <timepoint>MRI 4 minutes post injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To demonstrate noninferiority of gadobutrol compared to gadoteridol for: degree of contrast enhancement, border delineation, internal morphology, total number of lesions.</outcome>
      <timepoint>MRI 4 minutes post injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the safety profile of gadobutrol compared to gadoteridol after intravenous (IV) administration. Based on vital signs, physical examinations, clinical laboratory parameters and monitoring of adverse events.</outcome>
      <timepoint>MRI 4 minutes post injection.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Is referred for a contrast-enhanced MRI of the Central Nervous System based on current clinical symptoms or results of a previous imaging procedure. 
Has been fully informed about the study, including provisions of the Health Insurance Portability and Accountability Act (HIPAA) as applicable, and has consented to participate.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Has any contraindication to the MRI examinations or the use of Gd-containing contrast agents. 
Has a history of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents. 
Has severe cardiovascular disease (eg, acute myocardial infarction [&lt; 14 days], unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (&lt; 48 hours). 
Patients with acute renal insufficiency of any severity due to hepato-renal syndrome or in the perioperative liver transplantation period.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by an interactive voice response system (IVRS) is  used to accomplish a blind allocation.</concealment>
    <sequence>Computer generated random code.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>11/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>402</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3168</postcode>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer Australia Ltd</primarysponsorname>
    <primarysponsoraddress>875 Pacific Highway
Pymble, NSW 2073</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bayer Australia Ltd</fundingname>
      <fundingaddress>875 Pacific Highway
Pymble, NSW 2073</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study involves the use of Magnetic Resonance Imaging (MRI) contrast agents called gadobutrol (Gadovist®) Injection and ProHance® Injection. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the brain and spine. The results of the MRI with gadobutrol Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with ProHance®.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service (RPA Zone)</ethicname>
      <ethicaddress>Research Development Office, Level 8 Building 14, RPA Hospital, Camperdown, NSW, 2050</ethicaddress>
      <ethicapprovaldate>6/06/2008</ethicapprovaldate>
      <hrec>X07-0290</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Southern Health</ethicname>
      <ethicaddress>Research Directorate, Level 4 Main Block, 246 Clayton Road, Clayton, Victoria 3168</ethicaddress>
      <ethicapprovaldate>15/07/2008</ethicapprovaldate>
      <hrec>07211C</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Services Manager</name>
      <address>875 Pacific Highway
Pymble, NSW 2073</address>
      <phone>+61 2 9391 6147</phone>
      <fax />
      <email>medicalinformation@bayerhealthcare.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr John Patava</name>
      <address>875 Pacific Highway
Pymble, NSW 2073</address>
      <phone>+61 2 93916195</phone>
      <fax />
      <email>john.patava@bayerhealthcare.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>